Workers at Bangalore Airport transport carton boxes containing the Cowich Field vaccine, developed by Serum Institute of India, in Bangalore, India, Jan. 12, 2021.
Stringer | Xinhua | Getty Images
Singapore-India is preparing for the world’s largest mass vaccination practice starting Saturday.
The South Asian country plans to vaccinate some 300 million people, or more than 20% of the 1.3 billion people, against COVID-19 during the first phase of the exercise.
Indian airlines have begun delivering the first vaccine to Delhi and other major cities, including Kolkata, Ahmedabad and Bengaluru tech hub, Civil Aviation Minister Hardypsi tweeted. Ngh Puri earlier this week
Imaging priorities are given to healthcare agencies and other frontline workers, with about 30 million, followed by those over 50 and young and at high risk.
The launch will involve close cooperation between the federal and state governments.
India has also developed a digital portal called Co-WIN Vaccine Delivery Management System that provides real-time information about “Vaccine dosage, storage temperature and beneficiary tracking are individual,” according to the Ministry of Health.
“India’s expertise in vaccine production and experience in immunization campaigns prepares for the ‘Phase 1’ vaccination to begin this weekend, ” Eurasia Group South Asia analyst Akhil Bery wrote in the report. This week
“India has a long history of immunization campaigns, including a global immunization program that vaccines 55 million people annually and will rely on this expertise to distribute the coronavirus vaccine,” he added.
India’s drug regulators have approved restrictions on the use of two coronavirus vaccines in an emergency, both of which will be sent to various vaccination centers before Saturday.
One of them is a vaccine developed by the UK-Swedish company AstraZeneca and Oxford University, produced domestically by the Serum Institute of India (SII) and known locally as Covishield.
Another type of vaccine called Covaxin is: Developed domestically by India’s Bharat Biotech in conjunction with the state-run Indian Council of Medical Research. It is allowed for emergency use as clinical trials continue.
The Cowasin approval report has been criticized by some as regulators gave the green light shortly after asking Bharat Biotech to conduct further analysis.
On Tuesday, India’s health minister said the Indian government had signed an agreement to purchase 11 million doses of Covishield for 200 Indian rupees ($ 2.74) per drug. And cowasin 5.5 million doses for an average price of 206 rupees per shot, which tends to be cheaper than the private market.
Other applicants, including a second locally developed vaccine by Zydus Cadila, are in clinical trials.
India currently has more than 10.5 million cases of coronavirus infection after the United States. More than 151,000 people have died from COVID-19 in India, according to Johns Hopkins University. But the numbers reported daily showed a decrease in the number of active infections.
The largest country in South Asia is also the world’s largest producer of vaccines and is said to produce approximately 60% of all vaccines sold worldwide.
As a result, India’s production of the COVID vaccine is expected to play a vital role in driving immunization worldwide.
Eurasia Group’s Bery said that despite the government’s optimism, But two major risks could slow the launch of a vaccination campaign.
“First of all, vaccine capacity is limited, even in the best cases,” he said, adding that if local vaccine makers fail to produce the 600 million doses of the vaccine needed to vaccinate 300 million people. Start “India’s vaccination timing – and vaccine exports to other countries can be significantly delayed.”
The second risk is that India’s vaccine campaign will be heavily dependent on the state government. “Talents and expertise vary greatly,” Bery said. “Efficient co-ordination is needed between the federal and state governments, which is Modi’s strength. (Prime Minister Narendra) “